Nesting Leads Feng Nanjing High-technology Zone to promote the development of pharmaceutical innovation

With an investment of nearly 100 million yuan, the Nanjing High-energy District Biopharmaceutical Public Service Platform is located in Nanjing Biopharmaceutical Valley and was put into operation at the end of 2012. Since this year, Nanjing High-technology District Biopharmaceutical Public Service Platform has introduced 7 biopharmaceutical professionals to join the sea, the platform for deep-farming operations.
At the scene, Gu Kai, general manager of Nanjing High-technology District Biopharmaceutical Public Service Platform Co., Ltd., pointed to a high-intensity screening system equipment, said that the equipment is worth more than 600 million yuan, mainly used for in-body screening of synthetic compounds, is a necessary equipment in the process of research and development of new drugs. Next to it is an MRI device that tests the structure of the compound. The use and maintenance costs of the equipment are very high due to the constant filling of superconducting coils in the MRI with liquid nitrogen and liquid helium at a low temperature of minus 200 degrees C, which must be operated by a professional.
" biopharmaceuticals itself is a money-burning industry, these devices move millions of dollars, are biopharmaceutical enterprises to develop new drugs or do compound screening necessary, but the utilization rate is not high. Now with these devices and services provided by public service platforms, individual businesses do not have to invest repeatedly in the purchase of equipment, the burden is reduced a lot. Gu Kai said.
" this group of top professionals to join, is to let these high-sophisticated equipment really make the best use of, for the entire biopharmaceutical valley enterprises to provide professional and technical services. Gu Kai said that the platform has three sub-platforms for research and development technology, laboratory services and scientific and technological information services. The seven people hired this time are the top talents in the biopharmaceutical industry and will be the leaders of various sub-platforms. For example, Wang Fan, who studied for a ph.D. in the U.S. and 10 years in the field of biomedicine, this time as director of biology for the research and development technology platform, specializes in biomedical in-body screening. Dr. Liang Jie of the United States was appointed as the head of the laboratory service platform, he is not only familiar with the operation of the laboratory services, but also can independently help enterprises to build high-standard laboratories.
understood that at present, the platform has been equipped with 7 sea return 50 people technical service team. Wu Yongqian, an expert on the Central "Thousand People Program", founded Nanjing Pharmaceuticals Andersen Biotech Co., Ltd. in June this year in the Biopharmaceutical Valley, focusing on drug chemistry and research and development of new drugs. "Not only is the public service platform fast and easy to get data out, but the technicians are deeply involved in my projects, almost as a think tank." Wu Yongqian said that professional services let the company start like a fish in the water. The company recently received 60 million yuan of financing, the company's current valuation has reached 300 million yuan.
nanjing Science and Technology Commission responsible for the introduction, in promoting technological innovation, the industrial park has a common practice, is to build a public service platform. However, due to the lack of professional operators, services basically stay in such enterprises to use equipment stage, the government invested heavily in the construction of the platform utilization rate is not high. Nanjing High-tech District biomedical public service platform, by professional team to do professional things, to improve the innovation ability of small and medium-sized enterprises, promote the sustainable development of the industry has a vital role. (China High-tech Industry Guide)